Percheron Therapeutics Ltd. (PERCF)
0.002
0.00 (0.00%)
USD |
OTCM |
Jun 09, 16:00
Percheron Therapeutics PS Ratio
PS Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PS Ratio Data
| Date | Value |
|---|---|
| June 29, 2018 | 110.75 |
| June 28, 2018 | 91.76 |
| June 27, 2018 | 91.76 |
| June 26, 2018 | 91.76 |
| June 25, 2018 | 63.28 |
| June 22, 2018 | 63.28 |
| June 21, 2018 | 63.28 |
| June 20, 2018 | 63.28 |
| June 19, 2018 | 66.45 |
| June 18, 2018 | 66.45 |
| June 15, 2018 | 66.45 |
| June 14, 2018 | 66.45 |
| June 13, 2018 | 66.45 |
| June 12, 2018 | 66.45 |
| June 11, 2018 | 66.45 |
| June 08, 2018 | 66.45 |
| June 07, 2018 | 66.45 |
| June 06, 2018 | 66.45 |
| June 05, 2018 | 66.45 |
| June 04, 2018 | 66.45 |
| June 01, 2018 | 66.45 |
| May 31, 2018 | 66.45 |
| May 30, 2018 | 66.45 |
| May 29, 2018 | 66.45 |
| May 25, 2018 | 66.45 |
| Date | Value |
|---|---|
| May 24, 2018 | 66.45 |
| May 23, 2018 | 66.45 |
| May 22, 2018 | 66.45 |
| May 21, 2018 | 66.45 |
| May 18, 2018 | 66.45 |
| May 17, 2018 | 66.45 |
| May 16, 2018 | 66.45 |
| May 15, 2018 | 66.45 |
| May 14, 2018 | 66.45 |
| May 11, 2018 | 66.45 |
| May 10, 2018 | 66.45 |
| May 09, 2018 | 66.45 |
| May 08, 2018 | 66.45 |
| May 07, 2018 | 66.45 |
| May 04, 2018 | 66.45 |
| May 03, 2018 | 66.45 |
| May 02, 2018 | 66.45 |
| May 01, 2018 | 66.45 |
| April 30, 2018 | 66.45 |
| April 27, 2018 | 66.45 |
| April 26, 2018 | 66.45 |
| April 25, 2018 | 66.45 |
| April 24, 2018 | 66.45 |
| April 23, 2018 | 66.45 |
| April 20, 2018 | 66.45 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| Starpharma Holdings Ltd. | 25.09 |
| Neuren Pharmaceuticals Ltd. | 27.79 |
| Mayne Pharma Group Ltd. | 0.4794 |
| Acrux Ltd. | 3.802 |
| Invion Ltd. | -- |
PS Ratio Related Metrics
| Price | 0.002 |
| Earnings Yield | -270.0% |